amgen news - Search News

Amgen says obesity drug caused up to 20% weight loss

Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms

Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year,

Newsweek on MSN · 7h

Amgen Drug Delivers More Weight Loss Than Competitors

A new weight loss drug developed by Amgen may provide better results with fewer injections than current treatments such as Ozempic and Wegovy, according to the results of a recent trial. Trial participants who were obese or overweight lost an average of 20 percent of their body weight in 12 months without their weight loss plateauing,

Reuters · 1d

Amgen's weight-loss drug fails to impress in study; shares plunge

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Seeking Alpha17h

Amgen: Checks All The Wrong Boxes

In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...

22h

Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

pharmaphorum16h

Amgen's big reveal of obesity data falls a bit flat

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

13h

Amgen’s MariTide Phase 2 Success Drives Buy Rating Amid Promising Obesity Treatment Prospects

Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Amgen says obesity drug caused up to 20% weight loss

Related topics